For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Total revenue | 0 | 20 | ||
| General and administrative | 1,443.827 | 1,537.973 | ||
| Research and development | 2,729.891 | 906.68 | ||
| Collaboration credits | 1,658.248 | - | ||
| In-process r&d impairment | 0 | - | ||
| Change in fair value of contingent consideration | -1,721.033 | 120.234 | ||
| Total operating expenses | 794.437 | 2,564.887 | ||
| Operating (loss) income | -794.437 | -2,544.887 | ||
| Interest income, net | 201.822 | 342.102 | ||
| Other expense, net | -23.708 | -18.861 | ||
| Total other income, net | 178.114 | 323.241 | ||
| (loss) income before income tax benefit | -616.323 | - | ||
| Income tax benefit | -643.129 | - | ||
| Net (loss) income | 26.806 | -2,221.646 | ||
| Unrealized loss on marketable securities | - | -2.828 | ||
| Foreign currency translation adjustments | - | 21.467 | ||
| Net Income Loss From Continuing Operations Available To Common Shareholders Basic | 26.806 | - | ||
| Comprehensive income (loss) | - | -2,203.007 | ||
| Net (loss) income attributable to common shareholders | 26.806 | - | ||
| Net (loss) income per common share - basic (in usd per share) | 0.01 | -0.53 | ||
| Net (loss) income per common share - diluted (in usd per share) | 0.01 | -0.53 | ||
| Weighted average shares outstanding - basic (in shares) | 4,289,853 | 4,170,627 | ||
| Weighted average shares outstanding - diluted (in shares) | 4,361,740 | 4,170,627 | ||
KIORA PHARMACEUTICALS INC (KPHMW)
KIORA PHARMACEUTICALS INC (KPHMW)